Discover
llllllllll Ilumya (tildrakizumab-asmn) / Sun Pharma, AlmirallreSURFACE 1: A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010) (clinicaltrials.gov) - Aug 31, 2020 - P3; N=772; Completed; Sponsor: Sun Pharma Global FZE; Active, not recruiting --> Completedllllllllll Ilumya (tildrakizumab-asmn) / Sun Pharma, AlmirallreSURFACE 2: A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011) (clinicaltrials.gov) - Aug 31, 2020 - P3; N=1090; Completed; Sponsor: Sun Pharma Global FZE; Active, not recruiting --> Completedllllllllll Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Hakko Kirin; Tremfya (guselkumab) / J&J; Stelara (ustekinumab) / J&JCOBRA: Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab (clinicaltrials.gov) - Sep 1, 2020 - P4; N=260; Not yet recruiting; Sponsor: LEO Pharmallllllllll Xeljanz (tofacitinib) / Pfizer, Marche Polytechnic UniversityLast week, 26 items including the JAK inhibitor Boryeong tofacitinib were approved [Google translation] (Yakup Shinmoon) - Sep 1, 2020 - "...Boryeong tofacitinib tablet 5mg (Boryeong Pharmaceutical) containing tofacitinib aspartate as an oral JAK inhibitor used in the treatment of rheumatoid arthritis, etc. was approved...Boryeong tofacitinib tablet 5mg was approved as the first salt-modifying product of Gelzanz [sic] tablet (tofacitinib citrate), and unlike Gelzanz [sic] tablet 5mg, it has indications for rheumatoid arthritis and psoriatic arthritis, excluding ulcerative colitis. It is expected that the product will be available after November 2025, when the substance patent of Gelzance [sic] Tablet expires."
